Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28832953 | 0.91 | KMT2A (0.50) | KMT2APOLBNOD1MEN1FAAH | |
| SCHEMBL29552370 | 0.89 | NOD1 (0.57) | KMT2ANOD1MEN1FAAHMAPK1 | |
| SCHEMBL20450601 | 0.88 | KMT2A (0.51) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL12674184 | 0.88 | KMT2A (0.51) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL20450604 | 0.88 | KMT2A (0.51) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL25445241 | 0.88 | KMT2A (0.55) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL23080905 | 0.88 | KMT2A (0.55) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL25445566 | 0.88 | KMT2A (0.55) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL22074686 | 0.88 | KMT2A (0.51) | KMT2APOLBNOD1HDAC8L3MBTL1 | |
| SCHEMBL25445243 | 0.88 | KMT2A (0.51) | KMT2APOLBNOD1HDAC8L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295077-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295077-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN | GLP1R, GCG, GCGR | KMT2A 3435/4885POLB 4110/4885NOD1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.